SCHEMBL21484622

SCHEMBL21484622

N#C/C(=C\c1ccc(O)c(O)c1)C(=O)Nc1nc(-c2ccsc2)cs1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRE11 P49959 1/20 0.56
EGFR P00533 13/20 0.52
ERBB2 P04626 5/20 0.52
KDM4E B2RXH2 2/20 0.52
MEN1 O00255 2/20 0.52
ALDH1A1 P00352 2/20 0.52
LMNA P02545 2/20 0.52
TP53 P04637 2/20 0.52
CYP3A4 P08684 2/20 0.52
MAPT P10636 2/20 0.52
HPGD P15428 2/20 0.52
ALOX15 P16050 2/20 0.52
ALOX12 P18054 2/20 0.52
NFKB1 P19838 2/20 0.52
MAPK1 P28482 2/20 0.52
BLM P54132 2/20 0.52
PMP22 Q01453 2/20 0.52
KMT2A Q03164 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
HSD17B10 Q99714 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484629 0.88 EGFR (0.62) MRE11EGFRERBB2KDM4EMEN1
SCHEMBL21484889 0.88 EGFR (0.54) EGFRERBB2KDM4EMEN1ALDH1A1
SCHEMBL21484831 0.86 EGFR (0.52) EGFRERBB2KDM4EMEN1ALDH1A1
SCHEMBL21504876 0.86 EGFR (0.57) MRE11EGFRERBB2KDM4EMEN1
SCHEMBL21484888 0.86 EGFR (0.60) MRE11EGFRERBB2KDM4EMEN1
SCHEMBL21484607 0.86 MRE11 (0.56) MRE11EGFRERBB2KDM4EMEN1
SCHEMBL21484650 0.86 PTGS2 (0.64) MRE11EGFRERBB2KDM4EMEN1
SCHEMBL21484837 0.86 LMNA (0.54) EGFRERBB2KDM4EMEN1ALDH1A1
SCHEMBL21484665 0.86 MRE11 (0.56) MRE11EGFRERBB2KDM4EMEN1
SCHEMBL21484810 0.85 EGFR (0.53) EGFRERBB2KDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11453663-B2 Substituted propanamides as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2022-09-27 US disclosed
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-03-10 US disclosed
CN-112351983-A Substituted propionamides as inhibitors of nucleases 马萨里克大学 2021-02-09 CN disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
WO-2019201867-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES DNASE1, RNASEH1, FEN1 MRE11 86/4885EGFR 2905/4885ERBB2 3827/4885
US-11453663-B2 Substituted propanamides as inhibitors of nucleases DNASE1, RNASEH1, FEN1 MRE11 86/4885EGFR 2905/4885ERBB2 3827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.